

## Defining a therapeutic window for kinase inhibitors in leukemia to avoid neutropenia

Kate McArthur<sup>1,2</sup>, Akshay A. D’Cruz<sup>3,4</sup>, David Segal<sup>1,2</sup>, Kurt Lackovic<sup>1,2</sup>, Andrew F. Wilks<sup>1</sup>, Joanne A. O’Donnell<sup>1,2,5</sup>, Cameron J. Nowell<sup>6</sup>, Motti Gerlic<sup>1,7</sup>, David C.S. Huang<sup>1,2</sup>, Christopher J. Burns<sup>1,2,8,\*</sup> and Ben A. Croker<sup>1,2,3,4,\*</sup>

<sup>1</sup> Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia

<sup>2</sup> Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia

<sup>3</sup> Division of Hematology/Oncology, Boston Children’s Hospital, Boston, MA, USA

<sup>4</sup> Department of Pediatrics, Harvard Medical School, Boston, MA, USA

<sup>5</sup> Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA, USA

<sup>6</sup> Monash Institute of Pharmaceutical Sciences, Melbourne, VIC, Australia

<sup>7</sup> Department of Clinical Microbiology and Immunology, Tel Aviv University, Tel Aviv, Israel

<sup>8</sup> School of Chemistry, Bio21, The University of Melbourne, Melbourne, VIC, Australia

\* Christopher J. Burns and Ben A. Croker have contributed equally to this work

**Correspondence to:** Christopher J. Burns, **email:** burns@wehi.edu.au

Ben A. Croker, **email:** ben.croker@childrens.harvard.edu

**Keywords:** apoptosis, neutropenia, kinase inhibitors, hematopoietic progenitor cells, leukemia

**Received:** May 02, 2017

**Accepted:** June 09, 2017

**Published:** July 28, 2017

Copyright: McArthur et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### ABSTRACT

**Neutropenia represents one of the major dose-limiting toxicities of many current cancer therapies. To circumvent the off-target effects of cytotoxic chemotherapeutics, kinase inhibitors are increasingly being used as an adjunct therapy to target leukemia. In this study, we conducted a screen of leukemic cell lines in parallel with primary neutrophils to identify kinase inhibitors with the capacity to induce apoptosis of myeloid and lymphoid cell lines whilst sparing primary mouse and human neutrophils. We have utilized a high-throughput live cell imaging platform to demonstrate that cytotoxic drugs have limited effects on neutrophil viability but are toxic to hematopoietic progenitor cells, with the exception of the topoisomerase I inhibitor SN-38. The parallel screening of kinase inhibitors revealed that mouse and human neutrophil viability is dependent on cyclin-dependent kinase (CDK) activity but surprisingly only partially dependent on PI3 kinase and JAK/STAT signaling, revealing dominant pathways contributing to neutrophil viability. Mcl-1 haploinsufficiency sensitized neutrophils to CDK inhibition, demonstrating that Mcl-1 is a direct target for CDK inhibitors. This study reveals a therapeutic window for the kinase inhibitors BEZ235, BMS-3, AZD7762, and (R)-BI-2536 to induce apoptosis of leukemia cell lines whilst maintaining immunocompetence and hemostasis.**

### INTRODUCTION

Acute Myeloid Leukaemia (AML) is a heterogeneous disease characterised by an abundance of mutations in genes encoding signalling proteins, transcription factors, tumor suppressors and chromatin modifying proteins [1]. Cytogenetic profiling and

molecular genetic analysis is used to stratify patients into low, intermediate and high-risk groups, and whilst low-risk groups respond well to conventional cytotoxic chemotherapy, the majority of patients do not [2]. Indeed, less than 40% of adults with AML are cured, with the situation being particularly poor for the elderly who often have co-morbid conditions, where median survival is

approximately 10 months [3]. Against this backdrop there has been a concerted effort over the last decade to develop targeted therapies for AML, with the aim to target specific genetic lesions driving oncogenesis [4]. In particular, there has been a considerable focus on the development of selective kinase inhibitors for the treatment of AML, such as FLT3 inhibitors for the ~30% of patients who possess activating FLT3 mutations [5, 6].

Targeted therapies have also been proposed [7] for the treatment of T cell acute lymphoblastic leukemias (T-ALLs). T-ALL displays a variety of genetic complexities arising from mutations in signalling proteins, transcription factors and tumor suppressors. BCR-ABL inhibitors such as imatinib, nilotinib and dasatinib may be of use to ALL patients with ABL fusion proteins [8].

Of the hematological toxicities associated with chemotherapy regimes, neutropenia is the most common dose-limiting side-effect [9-12]. Neutropenia renders the immune system incapable of effective responses to many types of pathogens, and the duration and severity is strongly linked to morbidity and mortality [9], with average mortality being shorter for patients with hematological malignancies compared to those with solid tumors [13]. In addition neutropenia is associated with a significant economic burden due to treatment and hospitalization [13].

To better understand the clinical potential of targeted therapies in leukemia and particularly AML, we have screened a library of 95 known and well-studied kinase inhibitors and examined the apoptosis-inducing effect of these compounds against a panel of leukemia lines. In conjunction, we have used a live-cell imaging platform previously developed by us to determine if these compounds also induce apoptosis of neutrophils and hematopoietic progenitor cells, as a method of assessing their potential to cause neutropenia. With this combined experimental design we have identified individual kinase inhibitors that provide a therapeutic window for the effective treatment of leukemias with minimal effects on neutrophil viability. In addition, the data obtained in our neutrophil viability screen has identified kinase targets whose inhibition significantly impacts neutrophil survival via effects on Mcl-1 and may contribute directly to neutropenia *in vivo*.

## RESULTS

### Effect of compounds on leukemia cell proliferation


A library of 95 discrete kinase inhibitors was established with activity across all kinase families in the human kinome (Table 1). All compounds in the collection have been studied extensively with broad kinome selectivity data for most compounds available

in the literature [18-20]. Many of the inhibitors are used therapeutically or are in advanced clinical development. In addition, the BH3 mimetic ABT-737 [21], a compound with potent activity against leukemias [22], was included as a control compound.

The activity of the kinase inhibitor collection against a panel of human leukemia cell lines was determined in cell viability assays run over 48 h using the Cell Titer Glo reagent. The cell lines examined consisted of five AML lines (MV4;11, HL-60, OCI-AML3, THP-1, U937), two chronic myeloid leukemia (CML) lines (K562 and KU-812), two T-cell leukemia lines (MOLT4, JURKAT), and three additional leukemia lines (EOL-1, HEL.92.1.7, MEG-01), representing eosinophilic leukemia, erythroleukemia and megakaryoblastic leukemia, respectively. Compounds in this collection displayed a wide diversity of responses across the panel of cell lines (Figure 1A, Table 2). A substantial number of compounds showed potent activity against both MV4;11 and EOL-1 cell lines, whereas other cell lines (HEL 92.1.7, THP-1 and MOLT-4) appeared largely resistant to effects on cellular viability over the timeframe of the experiment. A small number of compounds showed potent activity ( $IC_{50} \leq 10$  nM) across most of the cell lines examined. These pan-active compounds consist of the first-generation PI3K p110 $\alpha$  (PI3K $\alpha$ ) inhibitor PIK-75[23], the PLK1 inhibitor BI-2536[24], the PI3K/mTOR inhibitor BEZ-235[25], and the Chk1/2 inhibitor AZD-7762 [26]. Further study of a panel of reported PI3K/mTOR inhibitors in HL60 cells confirmed the results from the preliminary screen, with all compounds, including the clinical agent PKI-587, PF-04691502 and GDC-0941 possessing significant anti-proliferative activity (Figure 1B). Notably, compounds with selectivity for members of the PI3K family were significantly weaker in this assay (Figure 1B). Compounds possessing MEK inhibitory activity (PD-0325901, CI-1040) possessed potent activity selectively against the HL-60 cell line, further confirmed on repeat dose-response studies with the inclusion of the highly potent MEK inhibitors GSK-1120212 and PD-0325901 (Figure 1C).

### Effect of compounds on neutrophil survival

Using a high-throughput live cell imaging approach reported previously [15], we examined the effect of the kinase inhibitors on the viability of bone marrow neutrophils to determine their potential to cause neutropenia (Figure 2). Because G-CSF and GM-CSF are dominant regulators of granulopoiesis and neutrophil survival, and are commonly used in a clinical setting to mobilize hematopoietic stem cells into the blood and increase neutrophil production [27-31], we treated cells with these cytokines immediately prior to drug exposure. The addition of either cytokine prevents constitutive neutrophil apoptosis thereby increasing the window for detection of changes in viability induced by drug



**Figure 1: Effects of kinase inhibition on the proliferation of leukemia cells.** A. Human leukemia cell lines were treated with duplicate serial dilutions of kinase inhibitors and the effect on cell viability was determined by Cell Titer Glo assay after 48 hours. Data shown represents the mean IC<sub>50</sub> of each condition from 2 independent experiments. HL-60 cells were treated with serial dilutions of mTOR/PI3K B. and MEK C. inhibitors and the effect on cell viability was determined after 48 hours. Data shown is the mean ± SEM of 3 independent experiments. Note, in some instances error bars are smaller than symbols displayed.

**Table 1: Compound and reported target**

Compound	Reported Targets	Compound	Reported Targets	Compound	Reported Targets
ABT-737	Bcl-2 proteins	CYC-116	Aurora	PII03	PI3K p110 $\alpha$
ABT-869	RTK	CYT387	JAK1, JAK2, TYK2	PIK-294	PI3K p110 $\alpha$
AC220	FLT3, FMS, cKIT, PDGFR	Danuseritib	AUR, BCR-ABL, FGFR	PIK-75	PI3K p110 $\alpha$ , CDK7, CDK9
AG13958	VEGF	Dasatinib	AUR, BCR-ABL, FGFR	PIK-90	PI3K p110 $\alpha$
Akt-I-1	Akt1	E7080	VEGFR, FGFR, SCFR	PLX4720	B-RafV600E
Akt-I-1,2	Akt1/2	Erlotinib	EGFR	Purvalanol-B	CDK
AMG-47a	Lck	Flavopiridol	CDKs	R1487	p38 MAPK
AMG-Tie2-1	TIE-2	GDC-0941	PI3K	RHO-15	ROCK1
AS-252424	PI3K p110 $\gamma$	Gefitinib	EGFR	RWJ-67657	p38MAPK
AT-7519	CDKs	GSK690693	Akt1, Akt2 and Akt3	SB202190	p38 MAPK
AT9283	Aurora	GW441756	TrkA	SB203580	p38 MAPK
AV-412	EGFR	IC87114	PI3K p110 $\delta$	SB216763	GSK3
AV951	VEGFR	Imatinib	BCR-ABL	SB242235	p38 MAP
Axitinib	VEGF, PDGF, c-Kit	JNJ38877605	c-MET	SB590885	B-Raf
AZ-960	JAK1, JAK2, JAK3	JNJ7706621	CDK	SD-06	p38MAPK
AZD1480	JAK2	Ki20227	cFMS	SD169	p38 $\alpha$ MAP kinase
AZD6244	MEK	KU0063794	mTOR	SNS-032	CDK2, CDK7, CDK9
AZD7762	CHK	KU55933	ATM	SNS-314	Aurora
BEZ-235	PI3K, mTOR	KU57788	DNA-PK	Sorafenib	Raf & VEGFR
(R)-BI-2536	Plk1	Lapatinib	EGFR, ErbB-2	SR3677	ROCK-II
BI-D1870	RSK	Masatinib	c-Kit	SU-5402	FGFR, c-Kit
Bisindoylmaleimide X	PKC	Merck 5	JAK1, JAK2, JAK3, TYK2	SU-6668	VEGF, PDGFR and FGFR
BMS-3	LIMK	Motesanib	c-Kit, PDGFR, VEGFR	Sunitinib	cFMS, Flt3, Kit, PDGFR, RET & VEGFR
BMS-5	LIMK	MP-470	Flt3, Met, Kit, c-Ret, PDGFR	TAK-715	p38 MAPK
Bosutinib	Bcr-Abl, Src	Nilotinib	BCR-ABL, cKit, PDGFR	Tandutinib	FLT3, PDGF, c-Kit
BX795	PKD1, TBK1	Pazopanib	VEGF	TGX221	PI3-K p110 $\beta$
BX912	PKD1	PD0325901	MEK	TOVOK	EGFR, HER2
CC-401	JNK	PF-562271	FAK	Vandetanib	VEGFR, EGFR
CI-1033	EGFR	PF04217903	c-Met	Vargatef	VEGF, PDGFR, FGFR
CI-1040	MEK1, MKK5	PF431396	PYK2	VX-680	Aurora
CP-724714	ErbB2	PHA690509	CDK-A	VX702	p38 MAPK
CP690550	JAK1, JAK2, JAK3	PI-93	PI3K p110 $\alpha$	YM201636	PIK5

treatments.

In G-CSF-primed neutrophils, nine kinase inhibitors reduced the viability of neutrophils (Figure 2A) whereas in GM-CSF-primed neutrophils, 25 kinase inhibitors significantly reduced neutrophil viability (Figure 2B). Of the kinase inhibitors active in G-CSF-primed neutrophils, all but one was also active in the GM-CSF treated group (Figure 2C). Given that both G-CSF and GM-CSF signal through the Janus kinases (JAKs), it is intriguing that only some JAK inhibitors included in the library significantly affected neutrophil viability (AZ960, AZD1480 and AT9283), whereas others did not (CP690550, CYT387 and Merck 5). The most active compounds in this screen are the cyclin-dependent kinase (CDK) inhibitors (SNS-032 and Flavopiridol) and the PI3K p110 $\alpha$  inhibitor PIK-75, which all induced rapid cell death in our assay system. Moreover, PIK-75 and SNS-032 induced cell death with similar potencies (Figure 2E) and kinetic profiles (Figure 2F). In contrast to other PI3 kinase inhibitors examined in

this study (including PI-93, PI-103, PIK-90 and PIK-294), PIK-75 was unique in its ability to induce rapid neutrophil cell death, suggesting that off-target effects of PIK-75 are responsible for the observed toxicity (*vide infra*).

Human peripheral blood neutrophils from healthy donors were also studied to determine if kinase inhibitors elicit similar changes in lifespan to those of mouse neutrophils. Purified human neutrophils were primed for 1 h with G-CSF or GM-CSF, and then treated for 18 h with SNS-032, PIK-75, GDC-0941, BI2536, BEZ235, AZD7762, SB202 or SB203. In the absence of kinase inhibitors, neutrophils primed with G-CSF or GM-CSF maintained a viability of approximately 80%. Consistent with the data obtained from mouse bone marrow neutrophils, human peripheral blood neutrophils were sensitive to PIK-75 and SNS-032 but not the p38 inhibitors SB202190 and SB203580 (Figure 3). Human neutrophils were sensitive to BI2536, BEZ235 and AZD7762 however the IC50 for these inhibitors were at

**Table 2: IC50 of inhibitors on cell lines.**

Drug Name	m	SD	m	SD	m	SD	m	SD	m	SD	m	SD	m	SD	m	SD	m	SD	m	SD	m	SD	m	SD
ABT-737	0.05	0.03	3.52	0.04	0.53	0.23	2.91	0.2	10	0	1.88	0.03	6.12	5.08	0.71	0.32	0.14	0.03	6.2	1.31	10	0	4.41	1.45
ABT-869	0.01	0	10	0	10	0	5.22	6.76	9.49	0.45	10	0	10	0	10	0	0.01	0	10	0	10	0	10	0
AC220	0	0	9.13	1.23	10	0	6.12	5.49	10	0	9.86	0.2	6.33	5.19	9.88	0.18	0.01	0.01	10	0	10	0	3.36	2.6
AG13958	0	0	6.26	0.22	6.2	1.48	4.55	0.29	1.37	0.09	0.43	0.11	0.66	0.14	6.75	0.71	3.13	0.68	4.98	0.63	9.71	0.41	5.55	0.15
Akt-I-1	1.82	1.09	10	0	10	0	10	0	10	0	10	0	10	0	10	0	8.48	2.5	10	0	10	0	10	0
Akt-I-1,2	0.3	0.11	10	0	9.88	0.17	8.45	0.46	9.62	0.66	3.81	0.3	6.33	0.22	8.38	2.3	6.8	3.69	9.59	0.58	10	0	9.64	0.51
AMG-47a	0	0	2.7	0.32	0.34	0.08	2.93	1.26	0.02	0.01	0.01	0.01	0.01	0	2.5	1.41	0.36	0.07	0.17	0.07	1.3	0.04	4.03	0.3
AMG-Tie2-1	0	0.01	4.18	1.3	2.41	0.42	9.65	0.5	0.02	0.01	0.01	0	0.01	0	9.49	0.72	0.6	0.18	0.41	0.13	3.56	0.56	5.12	0.35
AP24534	0	0	1.18	0.03	0.65	0.11	0.82	0.15	0	0	0	0	0.01	0.01	1.38	1.12	0.01	0.01	0.3	0.02	1.21	0.62	0.58	0.11
AS-252424	1.53	0.49	10	0	10	0	10	0	9.58	0.72	6.02	0.4	10	0	10	0	3.26	1.74	3.18	0.56	10	0	8.01	0.08
AT-7519	0.1	0.01	1.79	0	0.14	0.02	0.27	0.01	1.18	0.23	1.56	0.36	1.41	0.44	0.49	0.1	0.1	0.02	0.32	0.05	0.24	0.07	0.15	0.03
AT9283	0.02	0.02	0.98	0.23	1.03	0.06	1.81	0.44	0.87	0.16	0.95	0.13	1.72	0.3	1.83	0.38	0.03	0.01	3.95	0.16	2.56	0.59	1.98	0.02
AV-412	0.14	0.1	1.69	0.1	0.95	0.37	1	0.35	1.48	0.4	0.87	0.01	1.88	1.39	0.93	0.16	0.15	0	1.21	0.17	0.91	0.03	0.66	0.07
AV951	0	0	10	0	7.66	0.72	10	0	0.41	0.13	0.17	0.02	0.15	0.07	9.1	1.28	0.52	0.07	10	0	10	0	9.02	1.39
Axitinib	0	0	7.87	3.02	6.09	5.54	2.62	1.56	0.64	0.16	0.19	0.01	0.21	0.02	7.43	3.63	2.5	0.98	8.89	1.57	10	0	3.97	3.56
AZ-960	0.29	0.23	0.29	0.01	0.48	0.1	0.43	0.05	1.92	0.67	0.62	0.05	1.86	1.49	1.51	0.31	0.43	0	0.69	0.04	2.03	1.97	0.17	0.03
AZD6244	0.6	0.53	10	0	0.12	0.02	10	0	7.91	2.85	0.5	0.03	1.96	0.82	10	0	5.24	1.62	0.07	0.02	7.01	0.46	9.18	1.16
AZD7762	0	0	0.2	0.05	0.45	0.05	0.44	0.08	0.18	0.09	0.23	0	0.18	0.1	0.15	0.12	0.01	0.01	0.17	0.02	0.17	0.02	0.12	0.01
BEZ-235	0.06	0.05	0.14	0.08	0.27	0.13	0.07	0.03	0.54	0.28	0.65	0.07	0.89	0.57	0.09	0.03	0.14	0.06	0.26	0.04	0.35	0.34	0.13	0.04
(R)-BI-2536	0.01	0	0.02	0.01	0.01	0	0.01	0	0.1	0.13	0.01	0	0.04	0.05	0.01	0	0.01	0	0.01	0	0.01	0	0.01	0.01
BI-D1870	0.99	0.71	4.7	1.74	3.36	1.36	4.07	1.72	8.13	1.73	3.37	0.17	2.03	1.28	4.61	0.37	1.25	0.2	1.02	0.26	2.4	0.17	3.29	0.45
Bisindolymaleimide X	0.65	0.36	3.83	0.56	2.91	1.17	2.64	0.28	6.04	0.83	4.34	0.14	5.63	4.25	3.82	1.42	1.45	0.72	3.44	0.02	4.67	1.26	3.53	0.11
BMS-2	0.29	0.07	10	0	9.43	0.81	10	0	7.93	2	7.63	2.7	5.87	4.57	10	0	0.82	0.25	8.88	1.58	9.74	0.37	10	0
BMS-3	0.28	0.22	0.46	0.12	0.42	0.07	0.23	0.05	0.78	0.28	0.45	0.03	0.9	0.91	0.55	0.02	0.4	0.02	0.52	0.12	0.56	0.12	0.22	0.02
BMS-5	1.07	1.15	10	0	10	0	10	0	10	0	10	0	10	0	10	0	10	0	10	0	10	0	10	0
Bosutinib	0.56	0.05	1.01	0.26	3.73	3.69	0.91	0.14	0.88	0.17	0.23	0.02	0.21	0.07	1.7	1.79	0.66	0.07	1.48	0.08	1.89	0.1	0.91	0.52
BX795	0.12	0.08	5.43	1.66	10	0	9.08	1.3	9.27	0.64	2.38	0.1	4.41	1.83	10	0	0.1	0.05	10	0	10	0	2.07	0.43
BX912	0.12	0.1	10	0	8.47	2.16	7.57	0.15	7.13	3.5	9.63	0.53	7.25	3.89	3.37	2.25	0.05	0.01	10	0	10	0	2.57	0.14
CC-401	0.55	0.34	10	0	9.24	1.08	10	0	10	0	8.34	0.61	10	0	10	0	0.35	0.06	4.93	1.47	10	0	4.93	2.58
CI-1033	0.09	0.01	1.97	0.14	1.69	0.9	1.73	0.41	3.22	0.8	0.86	0.12	1.43	0.1	1.87	0.41	0.37	0.03	1.51	0.13	1.93	0.19	0.67	0.04
CI-1040	2.52	1.99	10	0	0.3	0.08	10	0	9.13	0.76	0.64	0.5	0.49	0.41	9.86	0.19	6.33	4.25	0.13	0.06	10	0	7.3	3.23
CP-724714	0.78	0.63	10	0	10	0	10	0	10	0	6.94	4.32	10	0	10	0	2.14	0.32	10	0	10	0	10	0
CP690550	2.81	2.52	7.83	3.06	10	0	10	0	10	0	10	0	5	7.07	10	0	9.34	1.32	10	0	10	0	0.94	0.4
CYC-116	0.26	0.22	2.18	0.67	6.25	4.37	1.97	1.97	8.46	0.7	4.91	0.99	3.61	2.09	1.44	0.04	0.09	0.04	7.67	2.53	8.96	1.47	0.48	0.04
Danuserib	0.05	0.01	5.75	0.97	0.56	0.06	4.32	0.25	0.14	0.06	0.24	0.04	0.43	0.16	0.66	0.38	0.04	0.01	0.87	0.38	10	0	0.13	0.17
Dasatinib	0.01	0	9.86	0.2	10	0	7.55	2.54	0	0	0	0	0.01	0.01	6.75	4.59	1.08	0.92	8.26	0.21	10	0	9.33	0.95
E7080	0	0.01	7.44	3.62	7.5	3.54	10	0	5.79	1.38	2.66	0.89	4.82	1.63	10	0	0.5	0.18	10	0	10	0	10	0
Erlotinib	1.68	1.45	8.52	0.26	9.26	1.04	6.73	0.12	10	0	5.48	0.02	5.68	0.11	10	0	1.9	0.21	10	0	10	0	10	0
Flavopiridol	0.11	0.03	0.22	0.01	0.12	0	0.18	0.01	0.55	0.13	0.25	0.01	0.42	0.16	0.23	0.03	0.15	0.03	0.14	0.02	0.13	0.02	0.1	0.01
GDC-0941	0.62	0.42	10	0	0.68	0.64	3.46	0.22	8.39	2.8	10	0	9.1	1.28	0.52	0.33	0.39	0.11	0.34	0.02	4.64	4.6	0.67	0.26
Gefitinib	0.9	0.61	9.42	0.82	10	0	5.59	2.16	10	0	4.96	0.72	9.1	1.27	8.34	2.34	2.22	0.71	7.32	1.61	10	0	5.53	2
GSK690693	1.75	1.18	10	0	6.3	0.21	0.41	0.16	10	0	10	0	10	0	0.26	0.17	2.35	0.68	10	0	10	0	0.25	0.01
GW441756	0.62	0.7	10	0	10	0	10	0	7.41	4.49	10	0	10	0	10	0	0.38	0.16	10	0	10	0	10	0
IC87114	4.43	3.95	10	0	10	0	10	0	10	0	10	0	10	0	10	0	5.77	1.75	10	0	10	0	5.09	6.94
Imatinib	0	0	10	0	10	0	9.55	0.64	0.25	0.12	0.12	0	0.16	0.08	10	0	8.82	1.71	10	0	10	0	10	0
JNJ38877605	7.43	4.8	10	0	10	0	10	0	10	0	10	0	10	0	10	0	10	0	10	0	10	0	10	0
JNJ7706621	1.32	0.23	4.8	0.34	1.76	0.58	3.39	0.17	5.23	1.01	3.48	0.27	5.91	0.92	7.81	1.79	1.28	0.22	2.86	0.44	2.05	0	1.09	0.4
Ki20227	0	0	10	0	10	0	10	0	10	0	9.44	0.79	10	0	10	0	6.62	1.51	10	0	10	0	5.25	0.76
KU0063794	0.06	0.04	5	2.08	4.97	0.12	4.12	2.01	4.94	1.73	4.39	0.55	5.12	3.07	3.32	0.01	0.61	0.1	2.04	0.62	3.54	2.97	0.63	0.18
KU55933	6.97	3.84	10	0	8.13	2.64	10	0	10	0	10	0	10	0	10	0	7.31	3.11	10	0	10	0	7.79	2.49
KU57788	3.6	1.94	8.94	0.38	6.2	4.55	9.14	1.21	10	0	10	0	7.44	1.58	9.93	0.1	2.52	2	1.51	0.35	6.59	4.83	3.87	1.84
Lapatinib	4.25	4.23	9.37	0.89	6.91	1.03	6.86	0.35	9.54	0.5	5.01	2.74	10	0	9.08	1.29	9.92	0.16	6.41	2.57	9.53	0.4	6.13	2.17
Masatinib	0	0	10	0	7.64	3.34	4.11	1.23	1.95	0.46	0.74	0.08	1.38	0.28	8.41	2.24	4.43	0.74	5.7	0.28	9.64	0.43	7.99	1.98
Merck -5	0.64	0.24	0.98	0.23	2.3	1.04	3.17	1.17	9.61	0.67	10	0	4.61	0.59	3	1.06	0.85	0.22	9.49	0.73	7.26	3.87	0.5	0.12
Motesanib	0.01	0	10	0	10	0	10	0	10	0	10	0	10	0	10	0	1.89	0.54	10	0	10	0	10	0
MP-470	1.11	0.61	5.12	6.91	10	0	10	0	9.09	1.58	1.2	0.92	5.29	1.27	10	0	2.6	1.29	6.2	4.43	10	0	6.75	4.6
Nilotinib	0	0	7.71	0.72	5.39	3.78	5.76	0.21	0.01	0	0.01	0	0.01	0	10	0	6.83	3.75	2.13	0.14	7.55	3.47	4.25	0.16
Pazopanib	0.02	0	10	0	9.48	0.74	10	0	9.11	1.54	1.68	0.09	5.55	1.85	10	0	4.73							

PI103	0.22	0.05	1.89	1.2	0.29	0.07	0.96	0.12	2.29	0.08	3.35	3.04	1.52	0.24	0.21	0.01	0.2	0.09	0.16	0	0.88	0.53	0.26	0.04
PIK-294	0.36	0.15	10	0	10	0	10	0	10	0	10	0	10	0	10	0	1.3	0.72	9.4	0.86	10	0	10	0
PIK-75	0.04	0.02	0.08	0	0.06	0.01	0.09	0	0.33	0.11	0.14	0.02	0.29	0.07	0.13	0.01	0.01	0	0.1	0.01	0.1	0.04	0.06	0.01
PIK-90	5.09	3.94	10	0	2.24	1.3	9.47	0.75	10	0	10	0	10	0	3.92	0.95	6.41	3.61	0.82	0.47	5.41	4.63	2.32	1.95
PIK-93	0.39	0.39	8.14	0.67	2.07	1.32	3.4	0.54	9.98	0.03	10	0	10	0	2.95	1.27	1.23	0.32	1.8	0.14	7.05	4.06	1.29	0.69
PLX4720	4.2	0.49	10	0	10	0	9.68	0.46	10	0	0.45	0.06	0.84	0.48	10	0	5.6	5.09	10	0	10	0	8.5	0.77
Purvalanol B	10	0	10	0	10	0	10	0	10	0	10	0	10	0	10	0	9.13	1.74	10	0	10	0	10	0
R1487	1.41	1.13	10	0	10	0	10	0	10	0	10	0	10	0	10	0	10	0	10	0	10	0	10	0
RHO-15	0.19	0.13	10	0	10	0	10	0	7.75	3.9	2.11	0.47	5.14	3.3	10	0	7.22	3.23	10	0	10	0	9.64	0.51
RWJ-67657	3.59	4.34	10	0	10	0	10	0	10	0	5.77	0.54	10	0	10	0	8.28	2.02	10	0	10	0	8.05	2.76
SB202190	3.68	2.38	10	0	10	0	10	0	10	0	9.36	0.91	6.83	4.48	10	0	7	3.12	10	0	10	0	6.6	4.81
SB203580	1.45	1.92	10	0	10	0	10	0	10	0	10	0	10	0	10	0	10	0	10	0	10	0	10	0
SB242235	0.51	0.21	10	0	10	0	10	0	10	0	10	0	2.18	0.64	10	0	6.16	2.66	10	0	10	0	10	0
SB590885	1.3	0.2	5.26	0.61	1.41	0.01	3.76	1.06	4.06	0.9	5.01	0.16	5.04	0.39	5.93	0.52	2.59	0.06	2.71	0.07	3.31	0.12	3.42	0.03
SD-06	1.87	2.26	10	0	10	0	10	0	10	0	10	0	10	0	5.03	7.03	5.67	5	10	0	10	0	10	0
SD169	5.12	5.64	10	0	10	0	10	0	10	0	10	0	10	0	10	0	10	0	10	0	10	0	10	0
SMI-4a	0.13	0.07	10	0	10	0	10	0	2.74	1.72	4.54	0.53	5.78	0.69	10	0	9.71	0.58	10	0	10	0	10	0
SNS-032	0.09	0.03	1.33	0.48	0.1	0.04	0.16	0.05	0.72	0.24	0.61	0.3	0.58	0.28	0.29	0.09	0.15	0.04	0.19	0.01	0.14	0.03	0.07	0.01
SNS-314	0.02	0	10	0	6.62	4.39	9.01	1.4	9.11	1.54	0.83	0.25	8.15	2.62	3.58	5.06	0.01	0	10	0	7.37	3.73	5.04	1.83
Sorafenib	0	0	10	0	5.73	0.91	10	0	9.94	0.1	3.79	2.84	6.28	5.26	10	0	0.01	0	5.46	1.56	10	0	5.33	2.86
SR3677	0.75	0.1	10	0	9.1	1.27	10	0	10	0	1.53	0.56	8.05	2.76	10	0	2.64	1.76	10	0	10	0	5.96	0.21
SU-5402	1.43	0.45	10	0	10	0	10	0	10	0	9.28	1.02	10	0	10	0	0.73	0.26	10	0	10	0	10	0
SU-6668	0.84	0.43	10	0	10	0	10	0	8.11	3.28	10	0	10	0	10	0	5.11	2.22	10	0	10	0	10	0
Sunitinib	0.01	0	2.61	0.01	1.46	0.14	1.62	0.33	4.75	0.62	1.56	0.68	2.39	0.43	2.54	0.33	0.01	0	1.02	0.24	1.8	0.93	1.16	0.81
TAK-715	2.33	0.65	10	0	10	0	9.58	0.54	7.41	2.38	6.14	1.4	7.37	3.38	10	0	7.8	2.57	10	0	10	0	4.11	1.34
Tandutinib	0.02	0	10	0	7.58	2.75	4.38	0.24	8.85	1.13	6.6	0.46	7.91	2.95	9.77	0.33	0.08	0.02	4.87	0.73	7.42	0.15	7.44	0.12
TGX221	0.43	0.31	10	0	10	0	9.84	0.22	9.16	0.82	10	0	10	0	10	0	0.65	0.37	9.72	0.39	10	0	9.85	0.21
TOVOK	0.68	0.23	1.94	0.23	1.8	0.34	2.11	0.07	5.72	0.57	2.71	0.28	5.02	4.75	2.37	0.61	0.44	0.08	3.36	1.17	4.31	1.68	2.06	0.86
Vandetanib	0.19	0.07	10	0	7.28	1.77	6.28	0.44	2.73	0.73	0.82	0.05	1.51	0.25	6.79	1.8	0.86	0.16	10	0	10	0	9.46	0.76
Vargatef	0	0.01	2.97	0.05	3.55	1.13	2.7	0.11	0.59	0.36	0.24	0.02	0.46	0.03	3.69	1.49	0.04	0	3.44	1.29	5.85	0.32	6.31	1.13
VX-680	0.07	0.02	7.99	0.45	2.45	1.52	4.96	0.49	0.43	0.08	0.18	0.02	0.53	0.11	2.59	0.88	0.05	0	0.8	0.03	5.75	6.01	5.46	5.21
VX702	5.5	2.69	10	0	10	0	10	0	10	0	10	0	10	0	10	0	10	0	10	0	10	0	10	0
YM201636	5.88	4.76	7.14	1.61	4.82	1.92	3.94	0.59	9.65	0.31	4.28	0.14	9.12	1.24	6.99	0.19	7.33	3.11	3.88	0.02	8.78	1.72	2.39	0.41


Values are shown in  $\mu\text{M}$ . For values less than 10 nM, they are represented as 0  $\mu\text{M}$ . m:mean; SD:standard deviation.

least 10-fold higher than for the cancer cell lines tested. Notably, human neutrophils were not sensitive to BI2536, BEZ235 and AZD7762 at the  $1\mu\text{M}$  concentration used to screen mouse bone marrow neutrophils. These data suggest that similar regulatory pathways control human neutrophil lifespan and point to kinase inhibitors that offer a therapeutic window to target cancer cells while sparing bone marrow and peripheral blood neutrophils.

To further explore the mechanisms underpinning the rapid neutrophil cell death induced by PIK-75 and SNS-032, we exposed neutrophils isolated from mice heterozygous for the *Mcl-1* allele or deficient in the dual apoptosis regulators *Bax* and *Bak*. The cytotoxicity was accelerated by the loss of a single allele of *Mcl-1* and completely abrogated by the loss of *Bak* and *Bax* (Figure 4). The loss of a single allele of *Mcl-1* reduced the  $\text{EC}_{50}$  for both SNS-032 and PIK-75 from 182 nM and 228 nM in wild-type cells to 80 nM and 57 nM in *Mcl-1*<sup>+/-</sup> cells, respectively. These data clearly indicate that neutrophil cell death induced by these compounds is mediated through the apoptotic pathway.

## Effect of compounds on hematopoietic myeloid progenitors

The kinase inhibitor library was also profiled against hematopoietic myeloid cells (defined as lin<sup>-</sup>c-Kit<sup>+</sup>Sca-1<sup>-</sup> cells) to determine the effects of these agents on cells capable of generating neutrophils. In contrast to the sensitivity of neutrophils to a broad range of kinase inhibitors, hematopoietic myeloid progenitor cells (HPC) were largely insensitive to the kinase inhibitor panel, with the exception of PIK-75, which was active against both G-CSF- and GM-CSF-treated HPC (Figure 5A and 5B). ABT-737, the small molecule antagonist of Bcl-2, Bcl-x<sub>L</sub> and Bcl-w, increased the death of hematopoietic progenitor cells (Figure 5C). In contrast, ABT-737 had no impact on mouse neutrophil viability (Figure 2). Similar results were obtained for a small panel of classical chemotherapeutics. Thus, a panel of eight commonly employed cytotoxic agents in leukemia showed profound activity against hematopoietic progenitor cells (Figure 5C) whereas only SN-38, the active metabolite of irinotecan, potentially decreased neutrophil viability (Figure 5D). Priming hematopoietic progenitor cells with GM-CSF, but not G-CSF, partially protected cells from the effects of vincristine and etoposide (Figure 5E).




**Figure 2: Viability of neutrophils in response to kinase inhibitors.** A. & B. Viability analysis from live cell imaging of primary murine bone-marrow neutrophils primed with either G-CSF (A) or GM-CSF (B) in response to a panel of kinase inhibitors [ $1\mu\text{M}$ ] over 24 hours. Bar graphs display percentage viability relative to G-CSF- or GM-CSF-only primed controls at 12 hours. Red bars denote significance,  $p < 0.05$  (corrected by Hommel's modification of a Bonferroni t test). C. Summary of data in A) & B) highlighting the kinase inhibitors that significantly altered neutrophil viability. D. Viability of saline-treated primary murine bone-marrow neutrophils compared to neutrophils primed with GM-CSF or G-CSF for 21 hours. E.  $\text{EC}_{50}$  values for PIK-75 and SNS-032 as calculated from kinetic live cell imaging data of murine bone-marrow neutrophils shown in F, concentrations as marked. For all above, data represent mean  $\pm$  SEM from three independent samples.


## DISCUSSION

The discovery and development of kinase inhibitors targeted to specific kinases and kinase families has been a focus for therapeutic development for over 15 years [32, 33]. Most kinase inhibitors bind to the highly conserved ATP binding site, and the vast majority possess a spectrum

of activities across the kinome [18-20, 34, 35]. Cell-based profiling of libraries of kinase inhibitors therefore offers the possibility of studying inhibition of multiple signaling networks simultaneously in an unbiased manner. The kinase inhibitory profile of active compounds from these screens, when available, can then be analysed to determine the specific kinases, or kinase combinations, driving



**Figure 3: Assessment of human neutrophil viability in response to kinase inhibitor treatment.** Human peripheral blood neutrophils from three healthy donors were primed with G-CSF or GM-CSF for 1 hour before addition of selected kinase inhibitors (as shown) or DMSO (control) at concentrations as indicated. Neutrophil viability was assessed after 18 hours of treatment, by propidium iodide exclusion measured by flow cytometry. Mean  $\pm$  SEM shown.



**Figure 4: Neutrophils heterozygous for the Mcl-1 allele are more sensitive to CDK inhibition.** **A.** SNS-032 and PIK75 induce Bak/Bax-dependent apoptosis in primary murine bone marrow neutrophils that is sensitized by haplo-insufficiency of Mcl-1. Dose-dependent changes to neutrophil viability induced by PIK-75 or SNS-032 were assessed by live cell imaging over 20 hours, with genotypes and concentrations as marked.  $EC_{50}$  values were calculated from the 12 hour time-point, data represent mean  $\pm$  SEM with  $n = 3$  per genotype. **B.** Immunoblot of Mcl-1 protein in bone marrow neutrophils from Mcl-1<sup>+/-</sup> mice, and from mouse embryonic fibroblasts as a control.




the phenotypic response. In addition, chemoproteomic methods can be employed to identify previously unknown biological targets of active compounds [36-38]. The deconvolution of active compounds from phenotypic screens using kinase-targeted compound libraries may therefore lead to the identification of new drug targets and target combinations for specific diseases, and a number of examples of this approach have been published recently, particularly from leukemia screens [39-41]. Furthermore, this approach may also be used to identify kinases whose inhibition may lead to potential toxicity [42, 43].

In this work we have screened a panel of kinase inhibitors against leukemia cell lines to identify compounds and kinase inhibitor classes that possess potent anti-leukemic activity. In parallel we have screened the same panel of compounds against primary mouse and human neutrophils to identify compounds and kinase inhibitory profiles that lead to neutrophil apoptosis, as a surrogate for predicting neutropenic potential. Screening the panel of kinase inhibitors against 12 leukemia cell lines identified four compounds (PIK-75, BI2536, BEZ235, AZD7762) that were potently cytotoxic to all lines examined. Thus, BI-2536, an inhibitor of polo-like kinases 1, 2 and 3 [24], and recently identified to potently inhibit the BET bromodomain BRD4 [44, 45], possessed an  $IC_{50} < 300$  nM across all cell lines examined. Given the polo-like kinases are intimately involved in cell division through association with tubulin [46], and that BRD4 inhibition can affect both cell cycle progression [47], recruitment of oncogenic transcription factors and expression of key survival proteins [48], this potent activity is unsurprising. Indeed, PLK1 is overexpressed in AML, and PLK inhibitors have been shown to possess activity in AML [49-51] and CML [52].

The potent activity of the pan PI3K/mTOR inhibitor BEZ-235 across the panel is also consistent with published data, and further supported by the activity of the recently described PI3K/mTOR inhibitors, PF-04691502 [53] and PKI-587 [54] against HL-60 cells (Figure 1C). BEZ-235 has shown activity in preclinical studies in AML [55] and has been shown to cause a decrease in Mcl-1 levels [56], a critical survival factor for AML and for neutrophils [57, 58]. Similarly, the Chk1 inhibitor AZD-7762 displayed high potency in cell lines, and selective Chk1 inhibitors have been shown to be cytotoxic to leukemia cells alone [59], or in combination with other drugs [60, 61]. The significant number of active agents against the FLT3-ITD positive AML line MV4;11, reflects the number of kinase inhibitors that possess FLT3 inhibitory activity either by design (e.g. AC220, tandutinib) or the known propensity of many kinase inhibitors to bind to FLT3 with high affinity [18]. The selective activity of MEK inhibitors GSK-1120212, PD-0325901 and CI-1040 against HL60 cells is also consistent with reported activity of MEK inhibitors in preclinical AML studies [62, 63], and indeed MEK inhibitors have been studied clinically in AML [64].

Taken together, these data clearly indicate our parallel screening approach can identify molecular targets, and indeed specific kinase inhibitors, with relevance to dose-limiting toxicities relevant to leukemia treatment.

Our parallel study exploring the effects of the kinase inhibitor library on neutrophil viability using real-time image analysis identified some surprising results. Our data clearly show that the potent CDK inhibitors flavopiridol and SNS-032 have a significant impact on neutrophil viability. That PIK-75, a nominally selective inhibitor of PI3K p110 $\alpha$  [23], induces neutrophil death with similar kinetics to SNS-032 is consistent with recent reports showing that this compound potently inhibits CDK7 and CDK9 [65, 66]. The cell death induced by SNS-032 and PIK-75 was accelerated by the loss of a single allele of Mcl-1 and completely abrogated by the loss of Bak and Bax indicating cell death proceeds via the intrinsic apoptotic pathway. Human neutrophils express CDK7 and CDK9, which influence transcription via the phosphorylation of RNA polymerase II [67]. The abrogation of protein synthesis by CDK9 inhibitors reduces intracellular levels of short-lived proteins such as Mcl-1, a critical pro-survival protein in neutrophils whose expression level is intimately linked with neutrophil survival [68-70]. Indeed, clinical experience with SNS-032 in patients with chronic lymphocytic leukemia and multiple myeloma identified neutropenia as the dose-limiting side-effect, thought to be a consequence of decreased expression of Mcl-1 and XIAP [71]. The effect of CDK9 inhibition on neutrophils has been reported previously [67], and CDK inhibitors have been proposed as potential anti-inflammatory agents via actions on Mcl-1 [72-74]. However, the mechanism of action of CDK inhibition has been only previously inferred from analysis of Mcl-1 protein levels [67, 70, 72, 75, 76]. Using a genetic approach, we now show that the loss of Mcl-1 protein increases the sensitivity of primary bone marrow neutrophils to SNS-032 and the inhibitor PIK-75. We cannot, however, exclude a role for PI3 kinase signaling in the death-inducing effects of PIK-75 because Mcl-1 expression is also regulated in part by PI3 kinase [77], though notably other PI3K inhibitors in the kinase panel did not induce neutrophil death with the same kinetics. The effect of inhibitors of the PI3K pathway on neutrophil viability was variable. Whilst the PI3K/mTOR inhibitor BEZ-235 had minimal impact, some neutrophil toxicity was observed for the inhibitors (PI-93, PI-103, PIK-294) over the timeframe of the experiment. Other investigators have noted important roles for PI3 kinase pathways in the viability of GM-CSF-stimulated neutrophils [78] which is consistent with our data (Figure 2B). The limited effect of Jak inhibitors on neutrophil viability is also consistent with previous studies using mice with a conditional deletion of STAT3 [79, 80]. However, the cytotoxicity of the JAK inhibitors TG-101348, AT-9283 and AZD-1480 may reflect undesired off-target activity of these



**Figure 5: Viability of hematopoietic myeloid progenitor cells in response to kinase inhibitors or chemotherapeutics. A. & B.** Viability analysis from live cell imaging of primary murine myeloid HPCs primed with either GM-CSF (A) or G-CSF (B) in response to a panel of kinase inhibitors [1 $\mu$ M] over 24 hours. Significant results ( $p < 0.05$ ) denoted in red (when adjusted for multiple comparison testing) or orange (not adjusted for multiple comparison testing). **(C & D)** Dose-dependent effects of common chemotherapeutics on GM-CSF-primed primary murine myeloid HPCs **C.** or GM-CSF-primed primary murine bone-marrow neutrophils **D.** as assessed by live cell imaging analysis (concentrations as marked). **E.** Comparison of G-CSF (red/orange) or GM-CSF (blue) priming of myeloid HPCs before treatment with chemotherapeutics as assessed by live cell imaging (concentrations as marked). Bar graphs display percentage viability relative to G-CSF- or GM-CSF-only primed controls at 12 hours. Mean  $\pm$  SEM with  $n = 3$  independent samples. \*  $p < 0.05$ . **F.** Venn diagram representing compounds that induce apoptosis of all leukemia cell lines tested ( $EC_{50} < 1 \mu\text{M}$ ), and their apoptosis-inducing potential on hematopoietic progenitor cells and neutrophils.

compounds (e.g. aurora kinase activity for TG-101348 and AT-9283; multiple targets for TG-101348 [44, 81]), and notably clinical trials of all three compounds have been discontinued.

In contrast to neutrophils, hematopoietic myeloid progenitor cells were less sensitive to the kinase inhibitor library, with the exception of PIK-75 (Figure 5), though this likely reflects the multikinase activity of this compound [66]. The small molecule antagonist of Bcl-2, Bcl-xL and Bcl-w, ABT-737, which showed minimal effects on neutrophils in our assay system, increased the death of hematopoietic myeloid progenitor cells. This is consistent with the reported role of Bcl-2 in the viability of hematopoietic progenitor cells [82]. By contrast, mature post-mitotic neutrophils were not sensitive to the panel of chemotherapeutics, with the exception of SN-38, whereas hematopoietic myeloid progenitor cells were exquisitely sensitive to these chemotherapeutics. Interestingly, although carboplatin and docetaxel induce neutropenia in the clinic [83, 84], no effects on hematopoietic myeloid progenitor cells or neutrophils were observed in these assays, suggesting that these cytotoxic drugs may induce the death of non-hematopoietic cells in the bone marrow niche or exert cytostatic effects on hematopoietic cells that impair neutrophil production.

In summary, our combined screening approach allows for the identification of specific compounds and kinase target combinations with utility in treating leukemia and lymphomas, whilst at the same time identifying whether these compounds have the potential to cause neutropenia through toxicity to neutrophils and their progenitors. Further, the kinase inhibitory properties of the compounds employed provides an opportunity to identify the dominant pathways controlling neutrophil viability. Our data demonstrates that compounds with significant CDK9 (and CDK7) activity are likely to be toxic to neutrophils. Conversely, PLK inhibitors and those targeting PIK3/mTOR and separately MEK and Chk1, are likely to have minimal neutropenic potential whilst having considerable activity against leukemias.

## MATERIALS AND METHODS

### Cell lines and culture

Leukemia and lymphoma cell lines were grown in RPMI containing 10% FCS. Cells were obtained from ATCC (HEL 92.1.7, Jurkat, MEG01, THP-1, MV4;11, KU-812, U937), the NCI (K562, HL-60, MOLT-4) or DSMZ (EOL-1, OCI-AML3) and used at low passage. Cell lines are routinely tested for mycoplasma and genotyped by short tandem repeating (STR) profiling to confirm identity.

### Cell proliferation assay

Compounds were obtained from SynMedChem and dissolved at 10  $\mu$ M in DMSO. Serial 2-fold dilutions of each compound were prepared in DMSO using a liquid handling robot (Janus, Perkin Elmer). Each dilution (100nL) was transferred to duplicate tissue culture plates containing 50  $\mu$ L of media containing  $5 \times 10^3$  cells using a 384 well pin tool. Cells were incubated for 48 h and cell viability was determined using Cell Titer Glow reagents as described by the manufacturer (Promega). Data was acquired using a luminescent plate reader (Envision, Perkin Elmer) and analysed using Activity Base (IDBS, Guilford, UK) and visualised using Spotfire (TIBCO, Palo Alto, CA) as described previously [14]. Each cell line was assayed in independent experiments on at least two occasions. The activity of PI3K/mTor and MEK inhibitors in HL-60 cells were validated using Cell Titer Glo assays in 96-well plates. Serial 2-fold dilutions of each compound were prepared in media containing 0.2% DMSO and 50  $\mu$ L of each dilution was added to  $10^4$  cells in 50  $\mu$ L of media. Cells were incubated for 48 h and cell viability was determined using Cell Titer Glow assay as described above.

### Mice

C57BL/6J, *Mcl1*<sup>+/-</sup>, *Bak*<sup>-/-</sup> *Bax*<sup>-/AvavCre</sup> and littermate controls on a C57BL/6J background were bred at the Walter and Eliza Hall Institute and analyzed at 6-10 weeks of age after CO<sub>2</sub> asphyxiation. All experiments were carried out in accordance with institutional animal ethics guidelines and approval.

### Neutrophil preparation

Mouse bone marrow neutrophils were prepared as described [15]. Neutrophils were resuspended in phenol red-free DMEM/10% FBS for imaging studies. The purity of neutrophil preparations was routinely 96%  $\pm$  4% (Mean  $\pm$  SD, *n* = 50) as assessed by cytology following May-Grünwald/Giemsa staining.

### Myeloid progenitor cell preparation

For purification of myeloid progenitor cells, bone marrow cells were collected in DMEM/10% FCS. After red cell lysis, cells were stained with biotin-conjugated antibodies against Ter119, Gr-1, Mac-1, B220, CD4, CD8 and IL-7R $\alpha$  and incubated with streptavidin-microbeads (Miltenyi Biotech). Lineage positive cells were depleted by magnetic separation using MACS LS columns and QuadroMACS™ separator magnets (Miltenyi Biotech). Hematopoietic myeloid progenitor cells that

were propidium iodide (PI) negative, lineage-negative, Sca-1 negative and c-Kit positive, were sorted and collected by flow cytometry on a FACSAria or Diva (BD Biosciences). For imaging studies, cells were resuspended in StemPro-34 SFM (Invitrogen). Cells were cultured in 10 ng/mL human G-CSF (Neupogen, Amgen), 10 ng/mL recombinant mouse GM-CSF or 10 ng/mL recombinant human GM-CSF.

## Human peripheral blood neutrophils

Peripheral blood was obtained from normal healthy donors in 2015 after obtaining informed written consent under an approved institutional review board protocol at Boston Children's Hospital. Donors were 18 years of age or older and had not taken anti-inflammatory medications during the 2 weeks before donating. Red blood cells were removed from 5 mL blood by hypotonic lysis in 45 mL 0.168 M  $\text{NH}_4\text{Cl}$ , 11.9 mM  $\text{NaHCO}_3$ , 10  $\mu\text{M}$  EDTA, pH7.3 on ice before immediate centrifugation at  $400 \times g$  for 5 min. Human neutrophils were then isolated on a three-layer Percoll gradient as described for mouse bone marrow neutrophils as described[16]. The purity of neutrophil preparations was  $93 \pm 1\%$  (mean  $\pm$  SD,  $n = 3$ ) as assessed by May-Grünwald Giemsa staining. Contaminating cells were comprised of eosinophils ( $7 \pm 1\%$ ). Neutrophils were resuspended in DMEM/10%FBS, and primed with 10 ng/mL recombinant human G-CSF (Amgen) or 10 ng/mL recombinant human GM-CSF (Leukine, Sargramostim) for 1 h. Compounds or DMSO carrier were added for 16 h. Viability was assessed by staining neutrophils with propidium iodide and analyzing on a BD Fortessa.

## Compounds

Kinase inhibitors were purchased from SYN kinase (Melbourne, Australia) and were used at 1  $\mu\text{M}$ , unless otherwise specified, with dilutions performed in assay buffer containing 0.1% DMSO. Chemotherapeutics, diluted in PBS immediately prior to treatment, were obtained from the following suppliers: ABT-737 (AbbVie); Bortezomib (Janssen); Carboplatin, Doxorubicin, Etoposide, Vincristine (DBL); Docetaxel (Aventis); Gemcitabine (Ebewe, InterPharma); and, 7-ethyl-10-hydroxycamptothecin (SN-38) (LKT Laboratories).

## Live cell imaging and quantitative analysis

Cells were labeled with 160 nM Cell Tracker Green (Invitrogen) and plated in 96- or 384-well optical bottom assay plates (Nunc, BD) at  $10^5$  or  $1.5 \times 10^3$  cells per well, respectively. Viability was monitored using 2  $\mu\text{g}/\text{mL}$  PI (Sigma). Images were captured every 30-60 min by the Zeiss Axiovert 200M Microscope at  $37^\circ\text{C}/10\% \text{CO}_2$ .

Quantitative analysis was performed using a custom-scripted MetaMorph (Molecular Devices) journal suite incorporating the count nuclei function, reconstruction & subtraction functions and Integrated Morphometry Analysis to select and analyze cells of interest. The MetaMorph script is available upon request.

## Statistical analysis

Unless otherwise specified, data are presented as mean  $\pm$  SEM of  $n = 3$ . Where  $n = 6$ , comparisons were made using a statistical modeling package CompareGrowthCurves [17]. Comparisons were performed using a Student's t-test and adjusted by Hommel's Modification of the Bonferroni t test.

## Author contributions

All authors contributed to the design of experiments, interpretation of data and manuscript preparation. K.M, A.D., D.S., K.L., J.A.O, C.J.N and B.A.C performed experiments.

## ACKNOWLEDGMENTS

We are grateful to Dr Suneet Agarwal for assistance with collection of human peripheral blood, and Rebecca Moss and Timothy Blackmore for assistance with Activity Base and Spotfire analysis. This work was supported by NIH Grant 5R01HL124209-2, the V Foundation for Cancer Research, Gabrielle's Angel Foundation for Cancer Research, and Alex's Lemonade Stand Foundation (B.A.C.). This work is supported by fellowships and grants from the Australian National Health and Medical Research Council (NHMRC) (Research Fellowships to DCSH; a Dora Lush Scholarship to J.A.O.; an Alan Harris Scholarship to K.M.; Project Grants to DCSH 1057742; Program Grants 1016701; Independent Research Institutes Infrastructure Support Scheme grant 9000220), the Cancer Council Victoria (grant-in-aid to DCSH), the Leukemia and Lymphoma Society (SCOR grants 7001-13), the Australian Cancer Research Foundation, a Victorian State Government Operational Infrastructure Support (OIS) grant, and Dyson Bequest funding (Dunn Fellowship) to CJB. ; Israel Science Foundation (ISF) 1416/15 (M.G.) and Varda and Boaz Dotan Research Center Individual Grant (M.G.).

## CONFLICTS OF INTEREST

The authors declare no financial conflicts of interest.

## REFERENCES

1. Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, Hoadley K, Triche TJ Jr, Laird PW, Baty JD, Fulton LL, Fulton R, Heath SE, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N Engl J Med*. 2013; 368:2059–74.
2. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. *Blood*. 2010; 115:453–74.
3. Pulsoni A, Pagano L, Latagliata R, Casini M, Cerri R, Crugnola M, De Paoli L, Di Bona E, Invernizzi R, Marmont F, Petti MC, Rigolin G, Ronco F, et al. Survival of elderly patients with acute myeloid leukemia. *Haematologica*. 2004; 89:296–302.
4. Ferrara F. New agents for acute myeloid leukemia: is it time for targeted therapies? *Expert Opin Investig Drugs*. 2012; 21:179–89.
5. Pemmaraju N, Kantarjian H, Andreeff M, Cortes J, Ravandi F. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. *Expert Opin Investig Drugs*. 2014; 23:943–54.
6. Kayser S, Levis MJ. FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations. *Leuk Lymphoma*. 2014; 55:243–55.
7. Van Vlierberghe P, Ferrando A. The molecular basis of T cell acute lymphoblastic leukemia. *J Clin Invest*. 2012; 122:3398–406.
8. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. *N Engl J Med*. 2006; 354:2531–41.
9. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. *Ann Intern Med*. 1966; 64:328–40.
10. Bodey GP. Infection in cancer patients. A continuing association. *Am J Med*. 1986; 81:11–26.
11. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. *Cancer*. 2005; 103:1916–24.
12. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. *Cancer*. 2004; 100:228–37.
13. Liou SY, Stephens JM, Carpiuc KT, Feng W, Botteman MF, Hay JW. Economic burden of hematological adverse effects in cancer patients: a systematic review. *Clin Drug Investig*. 2007; 27:381–96.
14. Eltahla AA, Lackovic K, Marquis C, Eden JS, White PA. A fluorescence-based high-throughput screen to identify small compound inhibitors of the genotype 3a hepatitis C virus RNA polymerase. *J Biomol Screen*. 2013; 18:1027–34.
15. Croker BA, O'Donnell JA, Nowell CJ, Metcalf D, Dewson G, Campbell KJ, Rogers KL, Hu Y, Smyth GK, Zhang JG, White M, Lackovic K, Cengia LH, et al. Fas-mediated neutrophil apoptosis is accelerated by Bid, Bak, and Bax and inhibited by Bcl-2 and Mcl-1. *Proc Natl Acad Sci USA*. 2011; 108:13135–40.
16. Croker BA, Lewis RS, Babon JJ, Mintern JD, Jenne DE, Metcalf D, Zhang JG, Cengia LH, O'Donnell JA, Roberts AW. Neutrophils require SHP1 to regulate IL-1 $\beta$  production and prevent inflammatory skin disease. *J Immunol*. 2011; 186:1131–39.
17. Elso CM, Roberts LJ, Smyth GK, Thomson RJ, Baldwin TM, Foote SJ, Handman E. Leishmaniasis host response loci (*Imr1-3*) modify disease severity through a Th1/Th2-independent pathway. *Genes Immun*. 2004; 5:93–100.
18. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. *Nat Biotechnol*. 2011; 29:1039–45.
19. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. Comprehensive analysis of kinase inhibitor selectivity. *Nat Biotechnol*. 2011; 29:1046–51.
20. Fedorov O, Marsden B, Pogacic V, Rellos P, Müller S, Bullock AN, Schwaller J, Sundström M, Knapp S. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. *Proc Natl Acad Sci USA*. 2007; 104:20523–28.
21. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, Adams JM, Roberts AW, Huang DC. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. *Cancer Cell*. 2006; 10:389–99.
22. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. *Cancer Cell*. 2006; 10:375–88.
23. Hayakawa M, Kawaguchi K, Kaizawa H, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S, Raynaud FI, Parker P, Workman P, Waterfield MD. Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110 $\alpha$  inhibitors. *Bioorg Med Chem*. 2007; 15:5837–44.
24. Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M, Gürtler U, Garin-Chesa P, Lieb S, Quant J, Grauert M, Adolf GR, Kraut N, et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. *Curr Biol*. 2007; 17:316–22.

25. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. *Mol Cancer Ther.* 2008; 7:1851–63.
26. Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, Green S, Haye HR, Horn CL, Janetka JW, Liu D, Mouchet E, Ready S, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. *Mol Cancer Ther.* 2008; 7:2955–66.
27. Metcalf D. The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors. *Blood.* 1986; 67:257–67.
28. Metcalf D. The colony-stimulating factors and cancer. *Nat Rev Cancer.* 2010; 10:425–34.
29. Begley CG, Lopez AF, Nicola NA, Warren DJ, Vadas MA, Sanderson CJ, Metcalf D. Purified colony-stimulating factors enhance the survival of human neutrophils and eosinophils in vitro: a rapid and sensitive microassay for colony-stimulating factors. *Blood.* 1986; 68:162–66.
30. Dührsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. *Blood.* 1988; 72:2074–81.
31. Morstyn G, Campbell L, Souza LM, Alton NK, Keech J, Green M, Sheridan W, Metcalf D, Fox R. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. *Lancet.* 1988; 1:667–72.
32. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. *Nat Rev Cancer.* 2009; 9:28–39.
33. Knapp S, Sundström M. Recently targeted kinases and their inhibitors-the path to clinical trials. *Curr Opin Pharmacol.* 2014; 17:58–63.
34. Bamborough P. System-based drug discovery within the human kinome. *Expert Opin Drug Discov.* 2012; 7:1053–70.
35. Uitdehaag JC, de Roos JA, van Doornmalen AM, Prinsen MB, de Man J, Tanizawa Y, Kawase Y, Yoshino K, Buijsman RC, Zaman GJ. Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use. *PLoS One.* 2014; 9:e92146.
36. Daub H, Olsen JV, Bairlein M, Gnad F, Oppermann FS, Körner R, Greff Z, Kéri G, Stemmann O, Mann M. Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. *Mol Cell.* 2008; 31:438–48.
37. Nita-Lazar A, Saito-Benz H, White FM. Quantitative phosphoproteomics by mass spectrometry: past, present, and future. *Proteomics.* 2008; 8:4433–43.
38. Hancock MK, Lebakken CS, Wang J, Bi K. Multi-pathway cellular analysis of compound selectivity. *Mol Biosyst.* 2010; 6:1834–43.
39. Kruse U, Pallasch CP, Bantscheff M, Eberhard D, Frenzel L, Ghidelli S, Maier SK, Werner T, Wendtner CM, Drewes G. Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells. *Leukemia.* 2011; 25:89–100.
40. Winter GE, Rix U, Carlson SM, Gleixner KV, Grebien F, Gridling M, Müller AC, Breitwieser FP, Bilban M, Colinge J, Valent P, Bennett KL, White FM, Superti-Furga G. Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. *Nat Chem Biol.* 2012; 8:905–12.
41. Tyner JW, Yang WF, Bankhead A 3rd, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, et al. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. *Cancer Res.* 2013; 73:285–96.
42. Olaharski AJ, Gonzaludo N, Bitter H, Goldstein D, Kirchner S, Uppal H, Kolaja K. Identification of a kinase profile that predicts chromosome damage induced by small molecule kinase inhibitors. *PLOS Comput Biol.* 2009; 5:e1000446.
43. Olaharski AJ, Bitter H, Gonzaludo N, Kondru R, Goldstein DM, Zabka TS, Lin H, Singer T, Kolaja K. Modeling bone marrow toxicity using kinase structural motifs and the inhibition profiles of small molecular kinase inhibitors. *Toxicol Sci.* 2010; 118:266–75.
44. Ember SW, Zhu JY, Olesen SH, Martin MP, Becker A, Berndt N, Georg GI, Schönbrunn E. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors. *ACS Chem Biol.* 2014; 9:1160–71.
45. Ciceri P, Müller S, O'Mahony A, Fedorov O, Filippakopoulos P, Hunt JP, Lasater EA, Pallares G, Picaud S, Wells C, Martin S, Wodicka LM, Shah NP, et al. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. *Nat Chem Biol.* 2014; 10:305–12.
46. van de Weerd BC, Medema RH. Polo-like kinases: a team in control of the division. *Cell Cycle.* 2006; 5:853–64.
47. Mochizuki K, Nishiyama A, Jang MK, Dey A, Ghosh A, Tamura T, Natsume H, Yao H, Ozato K. The bromodomain protein Brd4 stimulates G1 gene transcription and promotes progression to S phase. *J Biol Chem.* 2008; 283:9040–48.
48. Lovén J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, Bradner JE, Lee TI, Young RA. Selective inhibition of tumor oncogenes by disruption of super-enhancers. *Cell.* 2013; 153:320–34.
49. Renner AG, Dos Santos C, Recher C, Bailly C, Créancier L, Kruczynski A, Payrastre B, Manenti S. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. *Blood.* 2009; 114:659–62.

50. Casolaro A, Golay J, Albanese C, Ceruti R, Patton V, Cribioli S, Pezzoni A, Losa M, Texido G, Giussani U, Marchesi F, Amboldi N, Valsasina B, et al. The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. *PLoS One*. 2013; 8:e58424.
51. Gjertsen BT, Schöffski P. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. *Leukemia*. 2015; 29:11–19.
52. Gleixner KV, Ferenc V, Peter B, Gruze A, Meyer RA, Hadzijušufovic E, Cerny-Reiterer S, Mayerhofer M, Pickl WF, Sillaber C, Valent P. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. *Cancer Res*. 2010; 70:1513–23.
53. Cheng H, Bagrodia S, Bailey S, Edwards M, Hoffman J, Hu Q, Kania R, Knighton DR, Marx MA, Ninkovic S, Sun S, Zhang E. Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design. *MedChemComm*. 2010; 1:139–44.
54. Mallon R, Feldberg LR, Lucas J, Chaudhary I, Dehnhardt C, Santos ED, Chen Z, dos Santos O, Ayrál-Kaloustian S, Venkatesan A, Hollander I. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. *Clin Cancer Res*. 2011; 17:3193–203.
55. Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A, Pannetier M, Willems L, Park S, Macone A, Maira SM, Ifrah N, Dreyfus F, et al. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BE235 as a new therapeutic strategy for acute myeloid leukemia. *Clin Cancer Res*. 2010; 16:5424–35.
56. Müller A, Zang C, Chumduri C, Dörken B, Daniel PT, Scholz CW. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma. *Int J Cancer*. 2013; 133:1813–24.
57. Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD, Izon DJ, Zuber J, Rappaport AR, Herold MJ, Alexander WS, Lowe SW, Robb L, Strasser A. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. *Genes Dev*. 2012; 26:120–25.
58. Dzhagalov I, St John A, He YW. The antiapoptotic protein Mcl-1 is essential for the survival of neutrophils but not macrophages. *Blood*. 2007; 109:1620–26.
59. Schenk EL, Koh BD, Flatten KS, Peterson KL, Parry D, Hess AD, Smith BD, Karp JE, Karnitz LM, Kaufmann SH. Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro. *Clin Cancer Res*. 2012; 18:5364–73.
60. Chaudhuri L, Vincelette ND, Koh BD, Naylor RM, Flatten KS, Peterson KL, McNally A, Gojo I, Karp JE, Mesa RA, Sproat LO, Bogenberger JM, Kaufmann SH, Tibes R. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo. *Haematologica*. 2014; 99:688–96.
61. Dai Y, Chen S, Kmiecik M, Zhou L, Lin H, Pei XY, Grant S. The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair. *Mol Cancer Ther*. 2013; 12:878–89.
62. Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, Harris D, Konopleva M, Zhao S, Estey E, Andreeff M. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. *J Clin Invest*. 2001; 108:851–59.
63. Ricciardi MR, Scerpa MC, Bergamo P, Ciuffreda L, Petrucci MT, Chiaretti S, Tavarolo S, Mascolo MG, Abrams SL, Steelman LS, Tsao T, Marchetti A, Konopleva M, et al. Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for “vertical” and “lateral” combination strategies. *J Mol Med (Berl)*. 2012; 90:1133–44.
64. Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, et al. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. *Clin Cancer Res*. 2014; 20:490–8.
65. Thomas D, Powell JA, Vergez F, Segal DH, Nguyen NY, Baker A, Teh TC, Barry EF, Sarry JE, Lee EM, Nero TL, Jabbour AM, Pomilio G, et al. Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. *Blood*. 2013; 122:738–48.
66. Lemke J, von Karstedt S, Abd El Hay M, Conti A, Arce F, Montinaro A, Papenfuss K, El-Bahrawy MA, Walczak H. Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1. *Cell Death Differ*. 2014; 21:491–502.
67. Wang K, Hampson P, Hazeldine J, Krystof V, Strnad M, Pechan P, M J. Cyclin-dependent kinase 9 activity regulates neutrophil spontaneous apoptosis. *PLoS One*. 2012; 7:e30128.
68. Moulding DA, Quayle JA, Hart CA, Edwards SW. Mcl-1 expression in human neutrophils: regulation by cytokines and correlation with cell survival. *Blood*. 1998; 92:2495–502.
69. Scheel-Toellner D, Wang K, Henriquez NV, Webb PR, Craddock R, Pilling D, Akbar AN, Salmon M, Lord JM. Cytokine-mediated inhibition of apoptosis in non-transformed T cells and neutrophils can be dissociated from protein kinase B activation. *Eur J Immunol*. 2002; 32:486–93.
70. Leitch AE, Riley NA, Sheldrake TA, Festa M, Fox S, Duffin R, Haslett C, Rossi AG. The cyclin-dependent kinase inhibitor R-roscovitine down-regulates Mcl-1 to override pro-inflammatory signalling and drive neutrophil apoptosis. *Eur J Immunol*. 2010; 40:1127–38.

71. Tong WG, Chen R, Plunkett W, Siegel D, Sinha R, Harvey RD, Badros AZ, Popplewell L, Coutre S, Fox JA, Mahadocon K, Chen T, Kegley P, et al. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. *J Clin Oncol*. 2010; 28:3015–22.
72. Rossi AG, Sawatzky DA, Walker A, Ward C, Sheldrake TA, Riley NA, Caldicott A, Martinez-Losa M, Walker TR, Duffin R, Gray M, Crescenzi E, Martin MC, et al. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. *Nat Med*. 2006; 12:1056–64. Erratum in: *Nat Med*. 2006; 12:1434. Dosage error in article text.
73. Jackson RC, Radivoyevitch T. Modelling c-Abl Signalling in Activated Neutrophils: the Anti-inflammatory Effect of Seliciclib. *Biodiscovery*. 2013; 7:4.
74. Hellvard A, Zeitlmann L, Heiser U, Kehlen A, Niestroj A, Demuth HU, Koziel J, Delaleu N, Jan Potempa, Mydel P. Inhibition of CDK9 as a therapeutic strategy for inflammatory arthritis. *Sci Rep*. 2016; 6:31441.
75. Leitch AE, Lucas CD, Marwick JA, Duffin R, Haslett C, Rossi AG. Cyclin-dependent kinases 7 and 9 specifically regulate neutrophil transcription and their inhibition drives apoptosis to promote resolution of inflammation. *Cell Death Differ*. 2012; 19:1950–61.
76. Duffin R, Leitch AE, Sheldrake TA, Hallett JM, Meyer C, Fox S, Alessandri AL, Martin MC, Brady HJ, Teixeira MM, Dransfield I, Haslett C, Rossi AG. The CDK inhibitor, R-roscovitine, promotes eosinophil apoptosis by down-regulation of Mcl-1. *FEBS Lett*. 2009; 583:2540–46.
77. Derouet M, Thomas L, Cross A, Moots RJ, Edwards SW. Granulocyte macrophage colony-stimulating factor signaling and proteasome inhibition delay neutrophil apoptosis by increasing the stability of Mcl-1. *J Biol Chem*. 2004; 279:26915–21.
78. Cowburn AS, Cadwallader KA, Reed BJ, Farahi N, Chilvers ER. Role of PI3-kinase-dependent Bad phosphorylation and altered transcription in cytokine-mediated neutrophil survival. *Blood*. 2002; 100:2607–16.
79. Lee CK, Raz R, Gimeno R, Gertner R, Wistinghausen B, Takeshita K, DePinho RA, Levy DE. STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. *Immunity*. 2002; 17:63–72.
80. McLemore ML, Grewal S, Liu F, Archambault A, Poursine-Laurent J, Haug J, Link DC. STAT-3 activation is required for normal G-CSF-dependent proliferation and granulocytic differentiation. *Immunity*. 2001; 14:193–204.
81. Zhou T, Georgeon S, Moser R, Moore DJ, Cafilisch A, Hantschel O. Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348). *Leukemia*. 2014; 28:404–07.
82. Villunger A, Scott C, Bouillet P, Strasser A. Essential role for the BH3-only protein Bim but redundant roles for Bax, Bcl-2, and Bcl-w in the control of granulocyte survival. *Blood*. 2003; 101:2393–400.
83. Baker J, Ajani J, Scotté F, Winther D, Martin M, Apro MS, von Minckwitz G. Docetaxel-related side effects and their management. *Eur J Oncol Nurs*. 2009; 13:49–59.
84. Markman J, Zanotti K, Webster K, Belinson J, Peterson G, Kulp B, Markman M. Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy. *Gynecol Oncol*. 2004; 92:592–95.